Parkinson’s disease in the United States: market forecast to 2030 –

DUBLIN – (COMMERCIAL THREAD)–The “Parkinson’s disease – US market overview, epidemiology and forecast to 2030” report was added to offer.

The Parkinson’s disease market size in the United States was valued at $ 1,390.1 million in 2020, according to the report.

This market report offers an in-depth understanding of the historical and predicted epidemiology as well as United States Parkinson’s disease market trends.

The report provides current treatment practices, emerging drugs, individual therapies market share, current and forecasted Parkinson’s disease market size from 2018 to 2030 in the US market.

The report also covers current Parkinson’s disease treatment practice / algorithm, market drivers, market barriers, and unmet medical need to curate best opportunities and assess underlying market potential.


The total prevalent Parkinson’s disease population in the United States was estimated at 1,073,894 cases in 2020.

The Parkinson’s Epidemiology Division provides information on the historical and current patient pool as well as the forecast trend for the United States. It helps to recognize the causes of current and forecast trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the pool of diagnosed patients and their trends, as well as the assumptions made.

Main conclusions

The disease epidemiology covered in the report provides the historical and predicted epidemiology of Parkinson’s disease segmented as total number of prevalent cases of Parkinson’s disease, gender-specific cases of Parkinson’s disease, specific prevalence Parkinson’s disease severity, Parkinson’s disease cases by age and Parkinson’s disease cases by onset. The report includes the prevalent scenario of Parkinson’s disease symptoms in the United States from 2018 to 2030.

Chapters on Drugs

The Drugs chapter segment of the Parkinson’s disease report includes the detailed analysis of the marketed drugs for Parkinson’s disease and drugs in the late stage pipeline (Phase-III, Phase-II / III, Phase-II and Phase-I / II). It also helps to understand the details of clinical trials in Parkinson’s disease, expressive pharmacological action, agreements and collaborations, details of approvals and patents, the pros and cons of each drug included, as well as the latest. news and press releases.

Since 2014, the US FDA has approved many new therapies for Parkinson’s disease. This momentum is unprecedented in the history of drug development for Parkinson’s disease and a promising sign of the growing interest and investment of biopharmaceutical companies in this area.

Emerging drugs

Mesdopetam / IRL790 (Integrative Research Laboratories AB) works by opposing the dopamine D3 receptor and thereby neutralizing the physiological effects of the dopamine signal substance. The dopamine D3 receptor is genetically linked to an increased risk of involuntary movements, and patients with PD-levodopa-induced dyskinesia (DIL) have higher amounts of D3 receptors in parts of the brain essential for movement control. . Mesdopetam has successfully passed clinical studies demonstrating a good safety and tolerability profile.

In 2019, a 28-day phase IIa study was concluded evaluating the effect and tolerability of mesdopetam in PD patients with LID. The results of the study show clinically significant and quantitatively impressive effects on dyskinesias, assessed by two of the most widely used measures in the field: the standardized patient-reported journals (Hauser Journals) and the Parkinson’s disease (UPDRS). Patients reported marked improvements without additional side effects, demonstrating the ability of mesdopetam to provide a significant qualitative change in the daily life of patients.

A larger and longer phase IIb / III study to further assess the effects of mesdopetam in LID-PD began in November 2020. The phase IIb / III clinical study with mesdopetam is a randomized, duplicate study blind and placebo-controlled to evaluate the effect of mesdopetam in PD patients with troublesome dyskinesias.

The first results are expected in the first half of 2022

IPX203 (Amneal Pharmaceuticals) is an experimental sustained-release oral capsule formulation of carbidopa and levodopa, being investigated as a potential treatment for symptoms of advanced Parkinson’s disease. It is designed to have a similar onset of effect to IR CD-LD while providing a longer effect than other available oral levodopa products. The drug is currently being evaluated in two phase III studies in patients with Parkinson’s disease.

Market outlook

According to the publisher, the Parkinson’s disease market in the United States is expected to evolve during the study period 2018-2030.

Currently, there is no disease-modifying treatment for PD, and management consists primarily of dopaminergic drugs. The most commonly used are preparations of levodopa, a precursor to dopamine, which is given in combination with a dopa-decarboxylase inhibitor, limiting some of the side effects, such as nausea. Dopamine agonists, such as ropinirole or rotigotine, are also used.

Monoamine oxidase B inhibitors, such as rasagiline and selegiline, and catechol-O-methyltransferase (COMT) inhibitors such as entacapone, can be used to reduce endogenous dopamine metabolism. These treatments can restore dopaminergic activity in the striatum, heralding improvements in the motor characteristics of PD. However, they do not address many non-motor characteristics, which are particularly debilitating for many patients. This is because in some cases, treatments can exacerbate some of the non-motor symptoms, such as postural hypotension and neuropsychiatric problems.

Drug use

This section focuses on the adoption of potential drugs that have recently been launched or are expected to be marketed during the study period 2018-2030. The analysis covers the use of drugs in the Parkinson’s disease market, the use of therapies by patients and the sales of each drug.

This helps to understand which drugs are most rapidly absorbed, the reasons for the maximum use of new drugs, and allows drugs to be compared based on market share and size, which again will be useful for studying the important factors in market adoption and in making financial and regulatory decisions.

Pipeline activities

The report provides information on different therapeutic candidates in Phase III, Phase II / III, Phase II and Phase I / II. It also analyzes the key players in Parkinson’s disease involved in the development of targeted therapies.

Major players include Addex Pharma, Annovis Bio Inc, Pharma Two B Ltd, AbbVie, Prevail Therapeutics, Axovant Gene Therapies, Denali Therapeutics, Neurocrine Biosciences and others, whose key products are expected to be launched in the US market by 20XX .

Development activities

The report covers detailed information on collaborations, acquisitions and mergers, licenses and patent details for emerging therapies for Parkinson’s disease.

KOL Views

To follow current market trends, we take the views of KOLs and SMEs working in the area of ​​Parkinson’s disease through primary research to fill data gaps and validate our secondary research. Their advice helps to understand and validate current and emerging treatment regimens or market trends for Parkinson’s disease. This will support clients in the potential treatment ahead by identifying the overall market scenario and unmet need.

Competitive intelligence analysis

The publisher performs competitive and market analysis of Parkinson’s disease market using various competitive intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG matrix, market entry strategies , etc. The inclusion of the analysis is entirely dependent on the data. availablity.

Scope of the report

  • The report covers a descriptive overview of Parkinson’s disease, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.

  • A comprehensive overview was provided on the epidemiology and treatment of Parkinson’s disease in the United States.

  • Additionally, a comprehensive account of current and emerging therapies for Parkinson’s disease is provided, as well as the evaluation of new therapies, which will impact the current therapeutic landscape.

  • A detailed review of the Parkinson’s disease market; historical and expected, is included in the report, covering drug awareness in the United States.

  • The report provides an advantage while developing business strategies by understanding the trends shaping and driving the global Parkinson’s disease market.

Companies mentioned

  • Sunovion Pharmaceuticals

  • Pharmaceutical Adamas

  • Neurocrine biosciences

  • Adamas Pharmaceutical

  • Pharmaceutical Supernus

  • Kyowa Kirin

  • AbbVie

  • AB integrative research laboratories

  • Annovis Bio Inc.

  • Cerevel Therapeutic

  • Amneal Pharmaceuticals

  • Pharma Two B

  • AbbVie

  • Addex Pharma SA

  • Mitsubishi Tanabe Pharma

  • Pharmaceutical Supernus

  • Voyager Therapeutics

  • Novo Nordisk

  • Aptinyx

  • Sunovion / Psychogenic

  • Alkahest / Grifols

  • Intracellular therapies

  • Eli Lilly and company

  • Alkahest / Grifols

  • Athira Pharma

  • Takeda

  • VistaGen Therapeutics

  • Eisai Inc.

  • UCB Biopharma

  • Neuraly

  • Therapeutic sage

  • Sun Pharma Advanced Research Company (SPARC)

  • Enter inside

  • Hoffmann-La Roche / Prothena Biosciences Limited

  • Theranexus

  • Pharmaceutical Bukwang

  • Beta of Cerevance

For more information on this report, visit

About Margie Peters

Check Also

Sun Pharma Q1FY23 figures: Exceed expectations, but with room for improvement

Sun Pharma released its Q1FY23 results last Friday with an overall pace – 4.8% revenue, …

Leave a Reply

Your email address will not be published.